Efficacy and tolerability of lumiracoxib 100mg once daily in knee osteoarthritis: A 13-week, randomized, double-blind study vs. placebo and celecoxib

Current Medical Research and Opinion

Volumn 21, Issue 4, 2005, Pages 517-526

  Lehmann, Reiner ^a   Brzosko, Marek ^b   Kopsa, Petr ^c   Nischik, Ruth ^d   Kreiss, Andreas ^e   Thurston, Helen ^f   Litschig, Stephane ^f   Sloan, Victor S ^f  

^a Klinische Forschung Berlin Buch   (Germany)

^b POMERANIAN MEDICAL UNIVERSITY   (Poland)

^c FAKULTNÍ THOMAYEROVA NEMOCNICE   (Czech Republic)

^d Zentrum fur Therapiestudien (ZET)   (Germany)

^e Novartis Pharma AG   (Germany)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Analgesics; Celecoxib; Cyclooxygenase 2 inhibitors; Knee; Lumiracoxib; Osteoarthritis; Pain

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; LUMIRACOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; INFECTION; INFESTATION; INFLUENZA; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; OUTCOME MEASURES IN CLINICAL TRIALS OSTEOARTHRITIS RESEARCH SOCIETY INTERNATIONAL RESPONDER RATE; OUTCOMES RESEARCH; PAIN ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; URINARY TRACT INFECTION; WESTERN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX SUBSCALE SCORE;

ACTIVITIES OF DAILY LIVING; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANIC CHEMICALS; OSTEOARTHRITIS, KNEE; PLACEBOS; PYRAZOLES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 18744412683     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X38196     Document Type: Article

References (43)

1. Reginster JY. The prevalence and burden of arthritis. Rheumatology 2002;41(Suppl 1):3-6
2. Sangha O. Epidemiology of rheumatic diseases. Rheumatology 2000;39(Suppl 2):3-12
3. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-9
4. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, Gunther K, Hauselmann H, Herrero-Beaumont G, Kaklamanis P, Lohmander S, Leeb B, Lequesne M, Mazieres B, Martin-Mola E, Pavelka K, Pendleton A, Punzi L, Serni U, Swoboda B, Verbruggen G, Zimmerman-Gorska I, Dougados M. Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-55
5. American College of Rheumatology. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000;43:I905-15
6. Schnitzer TJ. Update of ACR guidelines for osteoarthritis: role of the coxibs. J Pain Symptom Manage 2002;23(Suppl 4):S24-30
7. Dougados M. The role of anti-inflammatory drugs in the treatment of osteoarthritis: a European viewpoint. Clin Exp Rheumatol 2001;19(Suppl 25):S9-14
8. Moskowitz RW. The role of anti-inflammatory drugs in the treatment of osteoarthritis: a United States viewpoint. Clin Exp Rheumatol 2001;19(Suppl 25):S3-8
9. Hernandez-Diaz S, Garcia Rodriguez LA. Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med 2001;110(Suppl 3A):20S-7
10. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999;340:1888-99
11. Moore RA. The hidden costs of arthritis treatment and the cost of new therapy - the burden of non-steroidal anti-inflammatory drug gastropathy. Rheumatology 2002;41(Suppl 1):7-15
12. Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, Hubbard RC, Isakson PC, Verburg KM, Geis GS. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999;74:1095-105
13. Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM, Geis GS. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001;96(Suppl 4):1019-27
14. Cannon GW, Caldwell JR, Holt P, McLean B, Seidenberg B, Bolognese J, Ehrich E, Mukhopadhyay S, Daniels B. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group. Arthritis Rheum 2000;43:978-87
15. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ. VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-28
16. Brune K, Hinz B. Selective cyclooxygenase-2 inhibitors: similarities and differences. Scand J Rheumatol 2004;33:1-6
17. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004;18:790-804
18. Marshall PJ, Berry JC, Wasvary J, Van Duzer J, Scott G, Rordorf C, Milosavljev S, Fujimoto RA. The in vitro and in vivo selectivity of COX189, a new and highly selective inhibitor of COX-2. Ann Rheum Dis 2002;61(Suppl I):259 [Abstract SAT0013]
19. Hartmann S, Scott G, Rordorf C, Campestrini J, Branson J, Keller U. Lumiracoxib demonstrates high absolute bioavailability in healthy subjects. In: European collaboration: Towards drug development and rational drug therapy. Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics. Tulunay FC, Orme M, editors. Berlin: Springer-Verlag, 2003;pp 124 [Abstract P-199]
20. Scott G, Rordorf C, Blood P, Branson J, Milosavljev S, Greig G. Dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of COX189 in healthy subjects. Ann Rheum Dis 2002;61(Suppl I):242 [Abstract FRI0300]
21. Scott G, Branson J, Milosavljev S, Rordorf C, Haraoui B, Quellet J-P, Schell E. Lumiracoxib demonstrates dose-proportional and time-independent pharmacokinetics in patients with osteoarthritis of the knee. Ann Rheum Dis 2003;62(Suppl I):267 [Abstract FRI0235]
22. Scott G, Rordorf C, Reynolds C, Kalbag J, Looby M, Milosavljev S, Weaver M, Huff JP, Ruff DA. Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clin Pharmacokinet 2004;43:467-78
23. Dawson J, Jagher B, Toscano KT, Fujimoto RA, Quadros E. Lumiracoxib shows rapid distribution to inflamed sites in a rat tissue chamber model compared with rofecoxib and celecoxib. Ann Rheum Dis 2003;62(Suppl I):377 [Abstract AB0042]
24. Weaver ML, Flood DJ, Kimble EF, Fujimoto RA. Lumiracoxib demonstrates preferential distribution to inflamed tissue in the rat following a single oral dose: an effect not seen with other cyclooxygenase-2 inhibitors. Ann Rheum Dis 2003;62(Suppl 1):378 [Abstract AB0044]
25. Day RO. Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: a rheumatologist's perspective. Clin Exp Rheumatol 2001;19(Suppl 25):S59-62
26. Hawkey CJ, Svoboda P, Fiedorowicz-Fabrycy IF, Nasonov EL, Pikhlak EG, Cousin M, Gitton X, Hoexter G. Gastroduodenal safety and tolerability of lumiracoxib compared with ibuprofen and celecoxib in patients with osteoarthritis. J Rheumatol 2004;31:1804-10
27. Kivitz AJ, Nayiager S, Schimansky T, Gimona A, Thurston HJ, Hawkey C. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. Aliment Pharmacol Ther 2004;19:1189-98
28. Hawkey CJ, Farkouh M, Gitton X, Ehrsam E, Huels J, Richardson P. Therapeutic Arthritis Research and Gastrointestinal Event Trial of lumiracoxib - study design and patient demographics. Aliment Pharmacol Ther 2004;20:51-63
29. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A, Hawkey CJ. TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665-74
30. Tannenbaum H, Berenbaum F, Reginster J-Y, Zacher J, Robinson J, Poor G, Bliddal H, Uebelhart D, Adami S, Navarro F, Lee A, Moore A, Gimona A. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind study versus placebo and celecoxib. Ann Rheum Dis 2004;63:1419-26
31. Fleischmann R, Sheldon E, Maldonado Cocco J, Yu S, Dutta D, Usiskin K. A prospective randomized 13-week study evaluating the efficacy of lumiracoxib in patients with osteoarthritis of the knee. Ann Rheum Dis 2003;62(Suppl I):266 [Abstract FRI0233]
32. Benevolenskaya L, Tüzün S, Hagin E, Moore A, Gimona A. Lumiracoxib is effective in relieving symptoms of knee or hip osteoarthritis after 4 weeks of treatment: results from a randomized, placebo-controlled trial. Ann Rheum Dis 2003;62(Suppl I):270 [Abstract FRI0246]
33. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986;29:1039-49
34. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to anti-rheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40
35. Dougados M, Leclaire P, van der Heijde D, Bloch DA, Bellamy N, Altman RD. Response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative. Osteoarthritis Cartilage 2000;8:395-403
36. Pham T, Van Der Heijde D, Lassere M, Altman RD, Anderson JJ, Bellamy N, Hochberg M, Simon L, Strand V, Woodworth T, Dougados M. OMERACT-OARSI. Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria. J Rheumatol 2003;30:1648-54
37. Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, Bombardier C, Felson DT, Hochberg MC, Van Der Heijde D, Dougados M. Evaluation of clinically relevant changes in patient-reported outcomes in knee and hip osteoarthritis: the Minimal Clinically Important Improvement. Ann Rheum Dis 2005;64:29-33
38. McKenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith JB, Geis GS. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 2001;30:11-18
39. Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, Hubbard RC, Isakson PC, Verburg KM, Geis GS. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999;74:1095-105
40. Makarowski W, Zhao WW, Bevirt T, Recker DP. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage 2002;10:290-6
41. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Gimona A, Matchaba P, Hawkey CJ, Chesebro JH. TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004;364:675-84
42. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709-11
43. Vioxx: an unequal partnership between safety and efficacy. Lancet 2004;364:1287-8